# A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Under Non-fasting Conditions

> **NCT00865657** · PHASE1 · COMPLETED · sponsor: **Actavis Inc.** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Alprazolam 3 mg Extended Release Tablets, single dose
- **DRUG:** XANAX XR® 3 mg tablets, single dose

## Key facts

- **NCT ID:** NCT00865657
- **Lead sponsor:** Actavis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2005-09
- **Final completion:** 2005-09
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2010-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00865657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00865657, "A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Under Non-fasting Conditions". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00865657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*